Page last updated: 2024-11-13
brartemicin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
brartemicin: an inhibitor of tumor cell invasion from the actinomycete Nonomuraea sp.; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
brartemicin : A glycosyl glycoside derivative that consists of alpha,alpha-trehalose substituted at positions 6 and 6' by O-2,4-dihydroxy-6-methylbenzoyl groups. It is isolated from the culture broth of actinomycete, Nonomuraea, and has antitumor activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 44139747 |
| CHEMBL ID | 558549 |
| CHEBI ID | 65512 |
| MeSH ID | M0548263 |
Synonyms (5)
| Synonym |
|---|
| CHEMBL558549 |
| brartemicin |
| chebi:65512 , |
| 6-o-(2,4-dihydroxy-6-methylbenzoyl)-alpha-d-glucopyranosyl 6-o-(2,4-dihydroxy-6-methylbenzoyl)-alpha-d-glucopyranoside |
| Q27133957 |
Research Excerpts
Overview
Brartemicin is a trehalose-based inhibitor of tumor cell invasion. It is produced by the actinomycete of the genus Nonomuraea.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Brartemicin is a trehalose-based inhibitor of tumor cell invasion produced by the actinomycete of the genus Nonomuraea. " | ( Synthesis and evaluation of trehalose-based compounds as anti-invasive agents. Igarashi, Y; Jiang, YL; Liu, ZP; Miyanaga, S; Saiki, I; Tang, LQ, 2011) | 1.81 |
| "Brartemicin is a trehalose-based inhibitor of tumor cell invasion produced by the actinomycete of the genus Nonomuraea. " | ( Synthesis and structure-activity relationships studies of brartemicin analogs as anti-invasive agents. Han, XZ; Igarashi, Y; Jiang, YL; Liu, ZP; Miyanaga, S; Saiki, I; Tang, LQ, 2013) | 2.08 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (2)
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| antimicrobial agent | A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (3)
| Class | Description |
|---|---|
| resorcinols | Any benzenediol in which the two hydroxy groups are meta to one another. |
| glycosyl glycoside derivative | A disaccharide derivative that is formally obtained from a glycosyl glycoside. |
| benzoate ester | Esters of benzoic acid or substituted benzoic acids. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (22)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1263308 | Displacement of radioiodinated Man31-bovine serum albumin from biotin-tagged bovine mincle CRD after 2 hr by scintillation counting analysis relative to alpha,alpha-trehalose | 2015 | MedChemComm, Apr-10, Volume: 6, Issue:4 | The natural product brartemicin is a high affinity ligand for the carbohydrate-recognition domain of the macrophage receptor mincle. |
| AID1263307 | Displacement of radioiodinated Man31-bovine serum albumin from biotin-tagged bovine mincle CRD after 2 hr by scintillation counting analysis | 2015 | MedChemComm, Apr-10, Volume: 6, Issue:4 | The natural product brartemicin is a high affinity ligand for the carbohydrate-recognition domain of the macrophage receptor mincle. |
| AID1454991 | Immunostimulatory activity in mincle-/- C57BL/6 mouse GM-CSF derived BMDM assessed as increase in IL-6 release at 0.1 to 1 nM after 24 hrs by sandwich ELISA method | 2018 | Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3 | Lipidated Brartemicin Analogues Are Potent Th1-Stimulating Vaccine Adjuvants. |
| AID1454992 | Immunostimulatory activity in mincle-/- C57BL/6 mouse GM-CSF derived BMDM assessed as increase in IL-1beta release at 0.1 to 1 nM after 24 hrs by sandwich ELISA method | 2018 | Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3 | Lipidated Brartemicin Analogues Are Potent Th1-Stimulating Vaccine Adjuvants. |
| AID568283 | Cytotoxicity against mouse 26-L5 cells upto 10 ug/ml | 2011 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4 | Synthesis and evaluation of trehalose-based compounds as anti-invasive agents. |
| AID1454990 | Immunostimulatory activity in mincle-/- C57BL/6 mouse GM-CSF derived BMDM assessed as increase in MIP2 release at 0.1 to 1 nM after 24 hrs by sandwich ELISA method | 2018 | Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3 | Lipidated Brartemicin Analogues Are Potent Th1-Stimulating Vaccine Adjuvants. |
| AID425007 | Antiinvasive activity against mouse 26-L5 cells | 2009 | Journal of natural products, May-22, Volume: 72, Issue:5 | Brartemicin, an inhibitor of tumor cell invasion from the actinomycete Nonomuraea sp. |
| AID1454982 | Binding affinity to recombinant mouse mincle extracellular domain fused with human IgG Fc expressed in HEK293T cells at 0.1 nmol by ELISA | 2018 | Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3 | Lipidated Brartemicin Analogues Are Potent Th1-Stimulating Vaccine Adjuvants. |
| AID1454980 | Agonist activity at mincle in wild type C57BL/6 mouse GM-CSF derived BMDM assessed as increase in TNF release at 0.1 to 1 nmol after 24 hrs by sandwich ELISA | 2018 | Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3 | Lipidated Brartemicin Analogues Are Potent Th1-Stimulating Vaccine Adjuvants. |
| AID425009 | Inhibition of MMP2 | 2009 | Journal of natural products, May-22, Volume: 72, Issue:5 | Brartemicin, an inhibitor of tumor cell invasion from the actinomycete Nonomuraea sp. |
| AID425011 | Antiinvasive activity against mouse 26-L5 cells assessed as inhibition of cell migration | 2009 | Journal of natural products, May-22, Volume: 72, Issue:5 | Brartemicin, an inhibitor of tumor cell invasion from the actinomycete Nonomuraea sp. |
| AID425010 | Inhibition of MMP9 | 2009 | Journal of natural products, May-22, Volume: 72, Issue:5 | Brartemicin, an inhibitor of tumor cell invasion from the actinomycete Nonomuraea sp. |
| AID1454989 | Immunostimulatory activity in mincle-/- C57BL/6 mouse GM-CSF derived BMDM assessed as increase in TNF release at 0.1 to 1 nM after 24 hrs by sandwich ELISA method | 2018 | Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3 | Lipidated Brartemicin Analogues Are Potent Th1-Stimulating Vaccine Adjuvants. |
| AID1454996 | Toxicity in Atlantic horseshoe crab blood limulus amebocyte lysate by chromogenic endotoxin test | 2018 | Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3 | Lipidated Brartemicin Analogues Are Potent Th1-Stimulating Vaccine Adjuvants. |
| AID568281 | Antiinvasive activity against mouse 26-L5 cells by transwell migration assay | 2011 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4 | Synthesis and evaluation of trehalose-based compounds as anti-invasive agents. |
| AID425008 | Cytotoxicity against mouse 26-L5 cells at 10 ug/ml | 2009 | Journal of natural products, May-22, Volume: 72, Issue:5 | Brartemicin, an inhibitor of tumor cell invasion from the actinomycete Nonomuraea sp. |
| AID1454983 | Binding affinity to recombinant human mincle extracellular domain fused with human IgG Fc expressed in HEK293T cells at 0.1 nmol by ELISA | 2018 | Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3 | Lipidated Brartemicin Analogues Are Potent Th1-Stimulating Vaccine Adjuvants. |
| AID1454978 | Agonist activity at mincle in wild type C57BL/6 mouse GM-CSF derived BMDM assessed as increase in IL-1beta release at 0.1 to 1 nmol after 24 hrs by sandwich ELISA | 2018 | Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3 | Lipidated Brartemicin Analogues Are Potent Th1-Stimulating Vaccine Adjuvants. |
| AID1454997 | Agonist activity at mouse mincle coupled with FcRgamma expressed in 2B4-NFAT-GFP reporter cells up to 1 nmol after 18 hrs by flow cytometric analysis | 2018 | Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3 | Lipidated Brartemicin Analogues Are Potent Th1-Stimulating Vaccine Adjuvants. |
| AID1454979 | Agonist activity at mincle in wild type C57BL/6 mouse GM-CSF derived BMDM assessed as increase in MIP2 release at 0.1 to 1 nmol after 24 hrs by sandwich ELISA | 2018 | Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3 | Lipidated Brartemicin Analogues Are Potent Th1-Stimulating Vaccine Adjuvants. |
| AID425012 | Antiinvasive activity against mouse 26-L5 cells at 1 ug/ml | 2009 | Journal of natural products, May-22, Volume: 72, Issue:5 | Brartemicin, an inhibitor of tumor cell invasion from the actinomycete Nonomuraea sp. |
| AID1454977 | Agonist activity at mincle in wild type C57BL/6 mouse GM-CSF derived BMDM assessed as increase in IL-6 release at 0.1 to 1 nmol after 24 hrs by sandwich ELISA | 2018 | Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3 | Lipidated Brartemicin Analogues Are Potent Th1-Stimulating Vaccine Adjuvants. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||